Tag: Biotechnology
-
REGENXBIO v. Sarepta Therapeutics: Recombinant AAV Host Cells Are Not Products of Nature
On February 20, 2026, the Federal Circuit issued a significant decision clarifying the scope of patent eligibility for genetically engineered compositions in REGENXBIO Inc. v. Sarepta Therapeutics, Inc., No. 2024-1408 (Fed. Cir. Feb. 20, 2026). Reversing the District of Delaware, the court held that claims directed to cultured host cells containing recombinant nucleic acid molecules…
-
Seagen v. Daiichi Sankyo: Federal Circuit Reverses $41M Verdict on Written Description
The Federal Circuit’s December 2, 2025 decision in Seagen Inc. v. Daiichi Sankyo Co., No. 23-2424, continues a noticeable and consequential trend: the court’s growing willingness to overturn jury verdicts on written description and enablement grounds as a matter of law. In reversing a $41 million verdict and vacating findings of willful infringement, the panel…